Table 8.
Differences in the approach to a first line treatment of CSU in physicians who do and do not follow the guidelines
| Treatment | Compared groups | n | % (n) of physicians, who follow the guidelines | % (n) of physicians, who don’t follow the guidelines | X2 | p |
|---|---|---|---|---|---|---|
| First-generation H1-antihistamines | Administer | 173 | 15.4 (160) | 14.8 (13) | 0.026 | 0.873 |
| No | 953 | 84.6 (878) | 85.2 (75) | |||
| Second-generation H1-antihistamines at standard dose | Administer | 704 | 64 (664) | 45.5 (40) | 11.868 | 0.001 |
| No | 422 | 36 (374) | 54.5 (48) | |||
| Updosed second-generation H1-antihistamines | Administer | 540 | 47.8 (496) | 50.0 (44) | 0.160 | 0.690 |
| No | 586 | 52.2 (542) | 50.0 (44) | |||
| H2-antihistamines (e.g. famotidine or ranitidine) | Administer | 224 | 19.7 (204) | 22.7 (20) | 0.481 | 0.488 |
| No | 902 | 80.3 (834) | 77.3 (68) | |||
| Ciclosporin | Administer | 15 | 1.4 (15) | 0 | 1.289 | 0.256 |
| No | 1111 | 98.6 (1023) | 100 (88) | |||
| Omalizumab | Administer | 32 | 3.0 (31) | 1.1 (1) | 1.006 | 0.316 |
| No | 1094 | 97.0 (1007) | 98.9 (87) | |||
| Montelukast | Administer | 150 | 13.2 (137) | 14.8 (13) | 0.174 | 0.676 |
| No | 976 | 86.8 (901) | 85.2 (75) | |||
| Dapsone | Administer | 7 | 0.6 (6) | 1.1 (1) | 0.409 | 0.522 |
| No | 1119 | 99.4 (1032) | 98.9 (87) | |||
| Systemic corticosteroids (for less than 10 days) | Administer | 215 | 18.7 (194) | 23.9 (21) | 1.406 | 0.236 |
| No | 911 | 81.3 (844) | 76.1 (67) | |||
| Systemic corticosteroids (for more than 10 days in a row) | Administer | 16 | 1.5 (16) | 0 | 1.376 | 0.241 |
| No | 1110 | 98.5 (1022) | 100 (88) | |||
| Tricyclic antidepressants (e.g. doxepin) | Administer | 35 | 3.0 (31) | 4.5 (4) | 0.655 | 0.418 |
| No | 1091 | 97.0 (1007) | 95.5 (84) |
Values marked in bold indicate a statistically significant difference (p < 0.05)